key: cord-0936352-j1rp2mjo authors: Goligher, Ewan C.; Zampieri, Fernando; Calfee, Carolyn S.; Seymour, Christopher W. title: A manifesto for the future of ICU trials date: 2020-12-09 journal: Crit Care DOI: 10.1186/s13054-020-03393-5 sha: a7c4ad033cc91df7ef26f8d6fad7341211599598 doc_id: 936352 cord_uid: j1rp2mjo nan The intensive care unit (ICU) is both a challenging and opportune environment for the conduct of clinical trials. On the one hand, competing determinants of patient outcome (including multi-morbidity and pre-ICU illness trajectory) and the heterogeneity of critical illness syndromes attenuate the population-average treatment effect [1, 2] . On the other hand, the ICU is a controlled environment that facilitates monitoring of protocol adherence and outcome ascertainment. ICU trials may be improperly powered because of overly optimistic assumptions about the baseline event rate in the control group and about the predicted effect of treatment on that event rate [3, 4] . The treatment effect required to demonstrate statistically significant benefit often substantially exceeds what might be considered the minimum clinically relevant benefit, and consequently, trials sometimes are interpreted to show "no evidence of benefit" even when clinically relevant benefits are observed. The COVID-19 pandemic has shown that we need to (and can) find a way to deliver more effectively on trials in the ICU. The benefit of dexamethasone was demonstrated within just a few short months of the outbreak of the global pandemic [5] . Conversely, many tens of thousands of patients were treated with unproven and potentially harmful therapies outside of trials, and the benefit of certain interventions remains uncertain due to the challenges of completing trials of these rapidly adopted therapies. We therefore propose a manifesto for the future of ICU trials (Table 1) . 1 Think Bayesian Bayesian analysis is an alternate statistical paradigm that answers the question "what is the probability of treatment effect" in contrast to the traditional frequentist approach, which answers the question "what is the probability of these data, assuming no treatment effect?" Under the Bayesian framework, trial information is not biased by "looking at" the data, and the results can be continuously re-estimated and updated as additional information (i.e., patient outcomes) is added to the dataset [6] . To put it simply (and perhaps somewhat simplistically), conventional frequentist statistics views the entire trial as a single "coin flip"; technically, there is no information to draw conclusions until the trial is completed. By contrast, Bayesian statistics regards each individual patient's outcome as a "coin flip"; the estimated probability of benefit or harm can be continuously updated as information accumulates. We contend that the Bayesian approach is ideal because it (a) directly answers the questions of interest (probabilities of clinically relevant benefit, harm, or futility), thereby reducing the risk of a false "positive" or false "negative" conclusion; and (b) the continuously updated posterior permits maximally efficient trial adaptations in sample size and treatment allocation [7] . 2 Adapt when needed Most trials in COVID-19 adopted an adaptive trial design given deep uncertainty about actual event rates and treatment effects. Adaptive designs respond flexibly to observed event rates and treatment effect, avoiding the risk of underestimating sample size requirement because of overly optimistic predictions about event rates and treatment effect [8] . Adapting treatment allocation probabilities within the randomization algorithm (response-adaptive randomization) can also increase trial efficiency in trials with three or more arms by Open Access dropping poorly performing interventions and identifying treatment-responsive subgroups earlier (rather than waiting until the end of the trial to draw a conclusion). 3 Build a platform Platform trials leverage the infrastructure for recruitment, treatment allocation, outcome ascertainment, and analysis to evaluate multiple interventions for a single disease state or multiple disease states [8] . Just as "multiple games" can be played in a single "stadium, " multiple trials-including Phase II, III, or IV trials-can be run sequentially or concurrently on a single platform. RECOVERY and REMAP-CAP provide important examples of phase III platform trials in COVID-19 [9, 10] . I-SPY2 provides a useful example of a Phase II platform intended to test many potential interventions for breast cancer, prioritizing the most promising agents for Phase III trials [11] . I-SPY2 investigators have now teamed with intensivists to launch an adaptive platform trial (I-SPY COVID) for severe COVID-19, with a similar Phase II focus. 4 Understand the noise In critical illness syndromes, the specific biological and physiological mechanisms driving outcomes may vary considerably ("noise") between patients. Hence, the benefit of therapeutics ("signal") targeting those mechanisms will also vary. To increase the probability of demonstrating the benefit of therapy in treatment-responsive subgroups (where such benefit actually exists)-to find the signal in the noise-heterogeneity in treatment response needs to be characterized as much as possible before and during Phase III trials [12, 13] . Adaptive trials can be designed to take account of relevant biological/physiological heterogeneity and to facilitate the discovery of such heterogeneity during the trial [11] . 5 Be inclusive To ensure that trial results are truly generalizable, we need to ensure that appropriately diverse and representative patient populations are enrolled in clinical trials. Perhaps the best way to achieve this is to cast the widest possible net so that nearly every critically ill patient (including those outside traditional academic centers) has the opportunity to participate in a trial. 6 Embed discovery within care Trials are costly, data collection is labor-intensive, and finding patients can be difficult. Embedding trials-both electronically and culturally-offers a solution. Embedding trials within existing data repositories (e.g., clinical registries, electronic health records) to "find" patients, randomly assign treatments, collect data, and ascertain outcomes can increase efficiency and reduce costs. Trials can be embedded within the cul-ture of clinical practice to achieve continuous quality improvement through discovery and innovation, an approach referred to as "learning while doing" [14] . Utilizing the uncertainty of clinical decision-making as an opportunity for randomization could dramatically accelerate our capacity to improve care and outcomes for patients [15] . The culture of ICU healthcare delivery needs to increasingly see clinical trials as part of its core mission to deliver the very best possible care for patients. Trials are not ancillary to high-quality patient-centered care-they are integral to the mission. Implications of heterogeneity of treatment effect for reporting and analysis of randomized trials in critical care Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis Powering bias and clinically important treatment effects in randomized trials of critical illness Outcomes and statistical power in adult critical care randomized trials Dexamethasone in hospitalized patients with Covid-19-preliminary report Bayesian clinical trials Sensible medicine-balancing intervention and inaction during the COVID-19 pandemic Adaptive platform trials: definition, design, conduct and reporting considerations The RECOVERY Platform Writing Committee for the REMAP-CAP Investigators convenient online submission • thorough peer review by experienced researchers in your field • rapid publication on acceptance • support for research data I-SPY 2-toward more rapid progress in breast cancer treatment Applying precision medicine to trial design using physiology. Extracorporeal CO 2 removal for acute respiratory distress syndrome Subphenotypes in critical care: translation into clinical practice Optimizing the trade-off between learning and doing in a pandemic Fusing randomized trials with big data: the key to self-learning health care systems? Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations Not applicable.